Astellas registers Phase 1/2 gene therapy trial for ASP2767 in glaucoma optic nerve damage

Astellas had one notable registry update this week involving its glaucoma gene therapy program.

• ASP2767, a gene therapy for optic neuropathy due to glaucoma, is recruiting under a Phase 1/Phase 2 study sponsored by Astellas Pharma Global Development, Inc. This is an early development study of ASP2767 in people with open-angle glaucoma, marking the first time it will be given to humans.¹ The trial aims to check the safety of ASP2767 in people with open-angle glaucoma, how well they tolerate it, and to find the highest dose people can safely receive.¹ The study is listed with an estimated enrollment noted in the registry record and a primary completion date of 2030-07-31 (estimated).¹ Treatment is delivered as a single injection into one eye only, across both phases of the study.¹